Evidence map›Paper›PMID 40652263›Full record

ArticleVirology journal2025

Efficacy of phage vB_Ps_ZCPS13 in controlling Pan-drug-resistant Pseudomonas aeruginosa from urinary tract infections (UTIs) and eradicating biofilms from urinary catheters.

Amira A Mohamed, Emad M El-Zayat, Ayman El-Shibiny

Abstract read
In one paragraph

Article in Virology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Amira A MohamedCenter for Microbiology and Phage Therapy, Zewail City of Science and Technology, Giza, 12578, Egypt.
Emad M El-ZayatDepartment of Biotechnology, Faculty of Science, Cairo University, Giza, Egypt.
Ayman El-ShibinyCenter for Microbiology and Phage Therapy, Zewail City of Science and Technology, Giza, 12578, Egypt. aelshibiny@zewailcity.edu.eg.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPan-drug resistance (PDR) is a ticking time bomb, as it causes high human hospitalizations and mortality rates. For instance, Pseudomonas aeruginosa is associated with significant rates of urinary tract infections (UTIs) due to several reasons including antibiotic resistance, biofilm formation and the presence of various virulence factors. Consequently, there is an urgent need for safe and effective alternative antibacterials. Phage therapy is a promising alternative that uses naturally occurring bacteriophages (phages). Therefore, our present study investigated the isolation and characterization of a novel virulent phage (vB_Ps_ZCPS13) against the PDR Pseudomonas aeruginosa strain (Ps13).

methodsPhage vB_Ps_ZCPS13 was isolated from raw sewage water in Egypt during the springtime. The isolated phage was purified and amplified, followed by estimating its purity and genome size using pulsed-field gel electrophoresis (PFGE), morphology using transmission electron microscopy (TEM), antibacterial activity against other P. aeruginosa hosts, physiochemical stability studies, whole genome sequencing, antibiofilm activity on urinary catheters using scanning electron microscopy (SEM), and cytotoxicity assays against normal human skin fibroblast (HSF) cell lines.

resultsBased on vB_Ps_ZCPS13 morphology under TEM, the phage has been classified as a myovirus. In consistent with the PFGE results, DNA sequencing revealed a phage genome size of 92,443 bp, with lytic-associated genes and no antimicrobial resistance or virulence factors. Phage vB_Ps_ZCPS13 presented a wide host range of over 93% of tested clinical isolates having different multiple antibiotic resistance (MAR) indices. Furthermore, phage vB_Ps_ZCPS13 exhibited high efficiency in plaque formation (EOP ≥ 1) against 13% of the strains and exhibited low frequencies of bacteriophage insensitive mutants (BIM). The physical stability test against harsh environmental conditions revealed phage stability within a pH range of 3.0-11.0 and stable at temperatures below 70 °C. Phage vB_Ps_ZCPS13 also exposed a significant antibacterial activity in vitro across different MOIs, with the highest reduction in bacterial growth observed at lower MOIs. Furthermore, vB_Ps_ZCPS13 demonstrated potent biofilm inhibition and clearance capabilities, effectively eradicating P. aeruginosa from the urinary catheter surface. Moreover, the phage presented no cytotoxicity against normal human skin fibroblast (HSF) cell lines at high titer.

conclusionsOur study offers an effective phage as a therapeutic candidate against PDR Gram-negative P. aeruginosa infections, including catheter-associated urinary tract infections.

Indexed as

BiofilmsPhage TherapyPseudomonas aeruginosaPseudomonas InfectionsPseudomonas PhagesUrinary CathetersUrinary Tract InfectionsAnti-Bacterial AgentsDrug Resistance, Multiple, BacterialEgyptGenome, ViralHumansSewageAnti-Bacterial AgentsSewageBacteriophageBiofilmCatheter-associated urinary tract infections (CAUTIs)CathetersMyovirusPan-drug resistance (PDR)Phage therapyPseudomonas aeruginosaUrinary tract infections (UTIs)

Identifiers

PMID40652263
PMCPMC12255097

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.